Wize Pharma

Wize Pharma EV/EBITDA

Delisted·Jan 10, 2019

The EV/EBITDA (Enterprise Value to EBITDA) of Wize Pharma (WIZP) as of Nov 19, 2026 is -181.23. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -139.61 — a change of 29.81% (lower).

EV/EBITDA

-181.23

YoY

29.81%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Wize Pharma is 2020 -181.23 . EV/EBITDA (Enterprise Value to EBITDA) of Wize Pharma was 2019 -139.61 . It decreases by 29.81% lower compared to the previous year.

The Wize Pharma EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2014
32.86 USD
Jan 1, 2015
-189.25 USD
Jan 1, 2016
-702.00 USD
Jan 1, 2017
-300.98 USD
Jan 1, 2018
-122.64 USD
Jan 1, 2019
-139.61 USD
Jan 1, 2020
-181.23 USD
The Wize Pharma EV/EBITDA history
YEAREV/EBITDAYoY
-181.23+29.81%
-139.61+13.83%
-122.64-59.25%
-300.98-57.12%
-702.00+270.94%
-189.25-675.84%
32.86—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Wize Pharma Stock analysis

What does Wize Pharma do? Wize Pharma Inc. is a leading biopharmaceutical company specializing in the development and marketing of innovative products for the treatment of eye diseases. The company was founded in 1997 and is headquartered in Herzliya Pituach, Israel. It focuses on the research, development, manufacturing, and marketing of eye disease treatments. The company aims to become a leading brand in the field of eye health and offers high-quality services in eye care. Wize Pharma Inc. operates different divisions, with its main divisions being the development and marketing of eye therapeutics, including LO2A and LO2B. LO2A is an innovative therapy for dry eye, while LO2B is an intraoperative formulation used in glaucoma surgery. The company's products provide effective and sustainable solutions for the treatment of eye diseases. Wize Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Wize Pharma stock

EV/EBITDA (Enterprise Value to EBITDA) of Wize Pharma is -181.23 in 2020.

EV/EBITDA (Enterprise Value to EBITDA) of Wize Pharma changed from -139.61 to -181.23, representing a 29.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Wize Pharma since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Wize Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Wize Pharma

All Key Metrics — Wize Pharma